Hepatitis C

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.

Data Elements

DEMOGRAPHICS

Diagnosis
Age
Gender
Race / Ethnicity
BMI
Height / Weight
Genotype
Fibrosis Score

LABS

CBC
HDL
ALT / AST
HCV Viral Load
Platelets
Serum Creatinine
eGFR
HbA1C
SVR12 Outcome

PRIOR HISTORY

Prior Treatment Status
Prior Treatment Regimen
Duration of Therapy
Reason for Failure
Prior Transplant
Smoking Status
Illicit Drug Use

COMORBIDS

HIV Coinfection
Anxiety
Depression
Hypertension
Diabetes
Chronic Kidney Disease
Hyperlipidemia
Hemodialysis

PROVIDERS

Type (Physician, NP, PA)
Specialty
Academic vs Community
Specialty Pharmacy

PAYERS

Type (Commercial, Medicare, Medicaid, Dual Eligible)
Payer Name
Self-Pay and Patient Assistance
Eligibility
Correct PA form
Denial Reason

PA TIMELINE

Copay Amount
PA Submitted Date
Approval / Denial Date
Appeals Submitted

DISPENSING INFO

Current Treatment Regimen Rx
Intended Regimen
Actual Regimen
Duration
Dispensed Regimen
Gaps in Therapy

HCV Scientific Steering Committee

Trio’s unbiased insights have established a high level of integrity based on the Scientific Steering Committee expertise, diversity, and credibility to deliver transparent insight on the disease.

Nezam Afdhal, MD

Chairman – HCV Steering Committee
Professor of Medicine, Harvard Medical School
Beth Israel Deaconess Hospital (BIDMC) Boston, MA

Bruce Bacon, MD

James F. King, MD Endowed Chair in Gastroenterology at Saint Louis University (SLU), St. Louis, MO
Former President of the AASLD in 2004
Chair of the AASLD Foundation since 2013

Michael Curry, MD

Section Chief, Director of Liver Transplant, BIDMC, Boston MA
Associate Professor, Medicine, Harvard Medical School

Steven Flamm, MD

Professor of Medicine & Surgery, Division of Hepatology at Northwestern University, Chicago, IL
Chief of Transplantation Hepatology
Trustee of the AASLD Foundation

Naoky Tsai, MD

Private Practice – Honolulu, HI
Professor of Medicine – University of Hawaii

Zobair Younossi, MD, MPH

Chairman, Department of Medicine, Inova Fairfax Hospital, Fairfax, VA
Professor of Medicine, Virginia Commonwealth University
Chair of the Medical Advisory Committee of the National Capital Chapter of the ALF

COMMITTEE MEMBER ACCOMPLISHMENTS

Publication Journals

Annals of Internal Medicine
APS - American Physiological Society
Clinical Gastroenterology
Journal of Hepatology
World Journal of Gastroenterology
The New England Journal of Medicine
Liver International

Associations and Foundations

AASLD Foundation
American Board of Internal Medicine
ACG
ACP
AGA
American Liver Foundation
Hepatitis B Foundation
EASL
NIH

Advisory Board Affiliations

AbbVie
AEVI
Angion
Bristol-Myers Squibb
Gilead
Ligand
Merck
Salix
Spring Bank

Publications & Abstracts

2018

Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the TRIO Network

Preferences in clinical practice with glecaprevir/pibrentasvir (GLE-PIB), ledipasvir/sofosbuvir (LDF-SOF), and sofosbuvir/velpatasvir (SOF-VEL); data from the TRIO Network

Change in demographics of direct-acting antiviral (DAA) prescribed HCV patients from 2013 to 2018; data from 19,994 patients in the TRIO Network

Disparities in Accessing HCV care under Medicaid Programs Across the United States; Experience from the TRIO Network

Effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naïve, non-cirrhotic patients with HCV infection in the TRIO Network

Untreated HCV in HIV/HCV co-infection; data from the TRIO Network

Behavioral and clinical factors and direct acting antiviral (DAA) effectiveness in HCV/HIV co-infection; clinical experience from the TRIO Network

Changing Demographics Among Prescribed Hepatitis C populations, 2013-2017

Use of Elbasvir-Grazoprevir in Patients With Chronic Hepatitis C and Chronic Kidney Disease (CKD): Retrospective Analyses from Clinical Practice

Real-World Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses From the TRIO Network

The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection

Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO Network

Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load <6mm IU/ml: Analyses of Real-World Data from the TRIO Network

Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in the Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

2017

Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network

Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

Access to HCV Care for 31,154 Patients in the United States: Real-World Experience from the TRIO Network

Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network

Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)

Impact of treatment duration and ribavirin (RBV) addition on real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in select patient subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective data analyses from the Trio Network

Cure denied and cure delayed in Chronic Hepatitis C; monitoring non-start rates and increased time to start using real-world data from the TRIO Network

HCV Treatment Failure in the era of direct-acting antivirals (DAAs): Analyses of real-world data from the TRIO Network

Drivers of Therapy Choice in Genotype 1 HCV: Analyses of real-world data from the TRIO Network

Real-world patterns of therapy utilization and outcomes in 8,049 HCV patients: data from the TRIO Network

2016

No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients In the TRIO Network

Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)

Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real-Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network

Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network

2015

Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network

Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network

Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Evaluation of Access to Care in Patients Prescribed Sofosbuvir-containing Regimens; Data from the TRIO Network

Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

2014

Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network

Efficacy of Sofosbuvir and Simeprevir-based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network

Hepatitis C

Hepatitis C

​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.

Data Elements

DEMOGRAPHICS

LABS

PRIOR HISTORY

COMORBIDS

PROVIDERS

PAYERS

PA TIMELINE

DISPENSING INFO

HCV Scientific Steering Committee

Trio’s unbiased insights have established a high level of integrity based on the Scientific Steering Committee expertise, diversity, and credibility to deliver transparent insight on the disease.

Nezam Afdhal, MD

Bruce Bacon, MD

Michael Curry, MD

Steven Flamm, MD

Naoky Tsai, MD

Zobair Younossi, MD, MPH

COMMITTEE MEMBER ACCOMPLISHMENTS

Publication Journals

Associations and Foundations

Advisory Board Affiliations

Publications & Abstracts

2018

2017

2016

2015

2014

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.